164 related articles for article (PubMed ID: 34852368)
1. [Interdisciplinary recommendations for the treatment of advanced renal cell carcinoma].
Miller K; Bergmann L; Doehn C; Grünwald V; Gschwend JE; Ivanyi P; Kuczyk MA
Aktuelle Urol; 2022 Sep; 53(5):403-415. PubMed ID: 34852368
[TBL] [Abstract][Full Text] [Related]
2. [Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma].
Miller K; Bergmann L; Doehn C; Grünwald V; Gschwend JE; Ivanyi P; Keilholz U; Kuczyk MA
Aktuelle Urol; 2020 Dec; 51(6):572-581. PubMed ID: 33027832
[TBL] [Abstract][Full Text] [Related]
3. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Doehn C; Gschwend JE; Kuczyk MA
Aktuelle Urol; 2019 Sep; ():. PubMed ID: 31486061
[TBL] [Abstract][Full Text] [Related]
4. [Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].
Miller K; Bergmann L; Doehn C; Gschwend J; Keilholz U
Aktuelle Urol; 2017 Feb; 48(1):72-78. PubMed ID: 28403496
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Borchiellini D
Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
[TBL] [Abstract][Full Text] [Related]
6. Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.
Oudard S; Joly F; Geoffrois L; Laguerre B; Houede N; Barthelemy P; Gross-Goupil M; Vano Y; Lucidarme O; Bidault F; Kelkouli N; Slimane K; Escudier B
Clin Genitourin Cancer; 2016 Dec; 14(6):e595-e607. PubMed ID: 27283478
[TBL] [Abstract][Full Text] [Related]
7. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
Patel SB; Stenehjem DD; Gill DM; Tantravahi SK; Agarwal AM; Hsu J; Vuong W; Pal SK; Agarwal N
Clin Genitourin Cancer; 2016 Apr; 14(2):153-9. PubMed ID: 26781820
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
9. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Gschwend J; Keilholz U; Kuczyk M
Aktuelle Urol; 2014 Jan; 45(1):39-44. PubMed ID: 24500960
[TBL] [Abstract][Full Text] [Related]
10. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
11. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
12. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.
Tannir NM; Pal SK; Atkins MB
Oncologist; 2018 May; 23(5):540-555. PubMed ID: 29487224
[TBL] [Abstract][Full Text] [Related]
13. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy.
Buti S; Leonetti A; Dallatomasina A; Bersanelli M
Core Evid; 2016; 11():23-36. PubMed ID: 27621699
[TBL] [Abstract][Full Text] [Related]
14. [TKI 2.0 - changes in the medical treatment of renal cell carcinoma].
Stühler V; Kruck S; Hegemann M; Notohamiprodjo M; Todenhöfer T; Kröger N; Stenzl A; Bedke J
Urologe A; 2018 Mar; 57(3):314-322. PubMed ID: 28879504
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
Amzal B; Fu S; Meng J; Lister J; Karcher H
PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line.
Porta C; Giglione P; Paglino C
Expert Opin Pharmacother; 2016; 17(5):643-55. PubMed ID: 26630127
[TBL] [Abstract][Full Text] [Related]
18. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Doehn C; Grünwald V; Gschwend J; Kuczyk M
Aktuelle Urol; 2015 Mar; 46(2):151-7. PubMed ID: 25897537
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
Al-Salama ZT; Keating GM
Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]